Jacob Gottlieb‘s hedge fund, Visium Asset Management, has boosted its position in biotechnology company QLT Inc. (USA) (NASDAQ:QLTI), a new filing with the SEC revealed. Visium currently holds 3.5 ...

VANCOUVER, British Columbia-- (BUSINESS WIRE)--QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT” or the “Company”) announced today that it has signed definitive agreements on multiple separate transformative ...

Welcome to the QLT Inc. second quarter 2008 conference call. (Operator Instructions) At this time, I like to turn the conference over to Therese Hayes, Vice President Investor Relations and Corporate ...

QLT, Inc. (QLTI) will look to some like a failed pharmaceutical company with only one drug on the market, the sales of which have dropped almost 80% over the past 4 years. I propose another ...

Mortgage Receivable During the third quarter, the Company renegotiated the CAD $12 million second mortgage related to the sale of our land and building in August 2008. As a result, QLT received CAD $4 ...

VANCOUVER, June 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) announced today that QLT USA, Inc., its wholly-owned subsidiary, has ...

InSite Vision’s Board of Directors approved the revised merger agreement with QLT and determined that the previously announced unsolicited offer from a multi-national pharmaceutical company (the ...

InSite Vision Inc.INSV, which is set to be acquired by QLT Inc. QLTI, announced that the unsolicited offer from a global pharmaceutical company to acquire InSite in an all-cash transaction for $0.35 ...

TORONTO, Nov 28 (Reuters) - QLT Inc said on Wednesday that it planned to stop investing in new products and technology and would instead review all strategic alternatives, including the sale of some ...

QLT Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne (R) for the treatment of ...

QLT Inc.QLTI reported a second-quarter 2015 loss of 21 cents per share, wider than the Zacks Consensus Estimate of a loss of 9 cents and the year-ago loss of 17 cents. QLT did not report any revenue ...

(Reuters) - Canadian eye drug developer QLT Inc expects its synthetic retinoid program, an experimental treatment for some inherited eye diseases that can cause blindness, to be valued at up to $750 ...